Immunotherapy and targeted-therapy combinations mark a new era of kidney cancer treatment.
Publication
, Journal Article
Zhang, T; George, DJ
Published in: Nat Med
April 2021
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Nat Med
DOI
EISSN
1546-170X
Publication Date
April 2021
Volume
27
Issue
4
Start / End Page
586 / 588
Location
United States
Related Subject Headings
- Quinolines
- Phenylurea Compounds
- Kidney Neoplasms
- Immunotherapy
- Immunology
- Humans
- Everolimus
- Carcinoma, Renal Cell
- Antibodies, Monoclonal, Humanized
- 42 Health sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Zhang, T., & George, D. J. (2021). Immunotherapy and targeted-therapy combinations mark a new era of kidney cancer treatment. Nat Med, 27(4), 586–588. https://doi.org/10.1038/s41591-021-01320-x
Zhang, Tian, and Daniel J. George. “Immunotherapy and targeted-therapy combinations mark a new era of kidney cancer treatment.” Nat Med 27, no. 4 (April 2021): 586–88. https://doi.org/10.1038/s41591-021-01320-x.
Zhang T, George DJ. Immunotherapy and targeted-therapy combinations mark a new era of kidney cancer treatment. Nat Med. 2021 Apr;27(4):586–8.
Zhang, Tian, and Daniel J. George. “Immunotherapy and targeted-therapy combinations mark a new era of kidney cancer treatment.” Nat Med, vol. 27, no. 4, Apr. 2021, pp. 586–88. Pubmed, doi:10.1038/s41591-021-01320-x.
Zhang T, George DJ. Immunotherapy and targeted-therapy combinations mark a new era of kidney cancer treatment. Nat Med. 2021 Apr;27(4):586–588.
Published In
Nat Med
DOI
EISSN
1546-170X
Publication Date
April 2021
Volume
27
Issue
4
Start / End Page
586 / 588
Location
United States
Related Subject Headings
- Quinolines
- Phenylurea Compounds
- Kidney Neoplasms
- Immunotherapy
- Immunology
- Humans
- Everolimus
- Carcinoma, Renal Cell
- Antibodies, Monoclonal, Humanized
- 42 Health sciences